Gao et al. found that elevated level of VISTA in patients with prostate cancer after ipilimumab therapy, (52) which binds to its ligand, V-Set and Immunoglobulin domain containing 3 (VSIG-3) suppressing Teffs proliferation and activation (53). Here, VSIR is linked to Familial prostate cancer.